A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
Part of paid clinical trials in Rancho Santa Margarita, California.
- Sponsor
- Krystal Biotech, Inc.
- Study ID
- NCT07016750
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- DEB - Dystrophic Epidermolysis Bullosa
- Dominant Dystrophic Epidermolysis Bullosa
- Dystrophic Epidermolysis Bullosa
- Recessive Dystrophic Epidermolysis Bullosa
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Months - N/A
- Healthy Volunteers
- Not accepted
Interventions
- KB803 — BIOLOGICALOphthalmic suspension of replication-defective, non-integrating herpes simplex virus (HSV-1) expressing the human collagen VII protein
- Placebo — DRUGVehicle
Study Details
KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
Key Dates
- Start date
- Jun 20, 2025
- Status verified
- Mar 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 16 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: KB803KB803
- Placebo Comparator: PlaceboVehicle
Primary Outcome Measure
To evaluate the safety and tolerability of KB803. [ Time Frame: 24 weeks ]
Central Contacts
- David Sweet, MD, PhD412-586-5830
- Brittani Agostini, RN, CCRC412-586-5830
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mission Dermatology Center | Rancho Santa Margarita | California | 92688 | |
| Skin Research Institute | Coral Gables | Florida | 33146 | |
| UMass Memorial Medical Center | Worcester | Massachusetts | 01605 | |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | |
| Texas Dermatology and Laser Specialists | San Antonio | Texas | 78218 |
Find similar trials in Rancho Santa Margarita, CA
Related Studies
- MSC EVs in Dystrophic Epidermolysis BullosaPHASE1/PHASE2 · Recruiting · Aegle Therapeutics · Phoenix, Arizona
- Long-Term Follow-up ProtocolRecruiting · Krystal Biotech, Inc. · Rancho Santa Margarita, California
- Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis BullosaPHASE1/PHASE2 · Recruiting · M. Peter Marinkovich · Redwood City, California
- Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)PHASE1/PHASE2 · Not Yet Recruiting · M. Peter Marinkovich · Redwood City, California